4.6 Review

Take a break - resveratrol in action on DNA

Journal

CARCINOGENESIS
Volume 29, Issue 2, Pages 321-332

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgm276

Keywords

-

Categories

Ask authors/readers for more resources

The phytochemical resveratrol (RV) has become a focus of intense research owing to its roles in promoting longevity and in cancer prevention. As an anticancer agent, RV has primarily been linked to growth and death regulatory pathways. There is now growing evidence that, under physiological conditions, RV additionally contributes to the maintenance of genome stability. Thus, at the stage of DNA damage formation, RV protects the genome as an antioxidant via inhibition of inflammation, suppression of metabolic carcinogen activation, de novo expression of genes that encode detoxifying proteins and possibly even via radical scavenging properties. However, results demonstrating RV-dependent DNA breakage in the presence of Cu(II) ions and inhibition of DNA polymerases alpha and delta produced some controversy regarding RV's role as a caretaker compound. Significantly, recent studies have revealed that activation of ataxia telangiectasia mutated and ataxia telangiectasia Rad3 related could be a central effect of RV that underlies cell-cycle regulation and the newly described activation of fidelity control mechanisms in DNA double-strand break repair involving Nbs1 and p53. In this review, we discuss the existing data on RV's direct and indirect effects on genome integrity, in the light of future chemopreventive and chemotherapeutic protocols involving RV or related compounds.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Oncology

Less Can Be More for Gene Dose and Drug Sensitivity

Susanne A. Gatz, Janet M. Shipley

CLINICAL CANCER RESEARCH (2015)

Article Genetics & Heredity

MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child

Susanne A. Gatz, Daniela Salles, Eva-Maria Jacobsen, Thilo Doerk, Tobias Rausch, Sevtap Aydin, Harald Surowy, Meta Volcic, Walther Vogel, Klaus-Michael Debatin, Adrian M. Stuetz, Klaus Schwarz, Ulrich Pannicke, Timo Hess, Jan O. Korbel, Ansgar S. Schulz, Johannes Schumacher, Lisa Wiesmueller

HUMAN MUTATION (2016)

Article Oncology

Chemotherapy Responsiveness in a Patient With Multiply Relapsed Ameloblastic Fibro-Odontosarcoma of the Maxilla

Susanne A. Gatz, Khin Thway, Henry Mandeville, Cyrus Kerawala, David MacVicar, Julia Chisholm

PEDIATRIC BLOOD & CANCER (2015)

Review Medicine, General & Internal

An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review

Gill Norman, Debra Fayter, Kate Lewis-Light, Julia Chisholm, Kieran McHugh, Daniel Levine, Meriel Jenney, Henry Mandeville, Suzanne Gatz, Bob Phillips

BMJ OPEN (2015)

Article Oncology

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours

Elisa Izquierdo, Lina Yuan, Sally George, Michael Hubank, Chris Jones, Paula Proszek, Janet Shipley, Susanne A. Gatz, Caedyn Stinson, Andrew S. Moore, Steven C. Clifford, Debbie Hicks, Janet C. Lindsey, Rebecca M. Hill, Thomas S. Jacques, Jane Chalker, Khin Thway, Simon O'Connor, Lynley Marshall, Lucas Moreno, Andrew Pearson, Louis Chesler, Brian A. Walker, David Gonzalez De Castro

ONCOTARGET (2017)

Article Oncology

Toxicity and Outcome of Children and Adolescents Participating in Phase I/II Trials of Novel Anticancer Drugs: The Royal Marsden Experience

Daniel A. Morgenstern, Darren Hargrave, Lynley V. Marshall, Susanne A. Gatz, Giuseppe Barone, Tracey Crowe, Kathy Pritchard-Jones, Stergios Zacharoulis, Donna L. Lancaster, Sucheta J. Vaidya, Julia C. Chisholm, Andrew D. J. Pearson, Lucas Moreno

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)

Article Oncology

Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy

Antonio Romo-Morales, Ewa Aladowicz, Julian Blagg, Susanne A. Gatz, Janet M. Shipley

PEDIATRIC BLOOD & CANCER (2019)

Article Oncology

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations

Sally L. George, Elisa Izquierdo, James Campbell, Eleni Koutroumanidou, Paula Proszek, Sabri Jamal, Deborah Hughes, Lina Yuan, Lynley V. Marshall, Fernando Carceller, Julia C. Chisholm, Sucheta Vaidya, Henry Mandeville, Paola Angelini, Ajla Wasti, Tomas Bexelius, Khin Thway, Susanne A. Gatz, Matthew Clarke, Bissan Al-Lazikani, Giuseppe Barone, John Anderson, Deborah A. Tweddle, David Gonzalez, Brian A. Walker, Jack Barton, Sarita Depani, Jessica Eze, Saira W. Ahmed, Lucas Moreno, Andrew Pearson, Janet Shipley, Chris Jones, Darren Hargrave, Thomas S. Jacques, Michael Hubank, Louis Chesler

EUROPEAN JOURNAL OF CANCER (2019)

Review Oncology

A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas

Susanne A. Gatz, Ewa Aladowicz, Michela Casanova, Julia C. Chisholm, Pamela R. Kearns, Simone Fulda, Birgit Geoerger, Beat W. Schaefer, Janet M. Shipley

FRONTIERS IN ONCOLOGY (2019)

Editorial Material Oncology

Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy

Olga Nigro, Andrea Ferrari, Michela Casanova, Daniel Orbach, Amaury Leruste, Susanne A. Gatz, Didier Frappaz, Maura Massimino

Summary: Pediatric cancers do not show the same enthusiasm for immunotherapy as adult cancers, but progress is being made in understanding PD-L1 expression, tumor mutational burden, and microsatellite instability in pediatric cancers. The side effects of immunotherapy are important considerations, and the unknown risks of late irAEs in pediatric patients are a concern.

TUMORI JOURNAL (2021)

Article Oncology

Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial

Anne-Sophie Defachelles, Emilie Bogart, Michela Casanova, Johannes H. M. Merks, Gianni Bisogno, Giuseppina Calareso, Soledad Gallego Melcon, Susanne Andrea Gatz, Marie-Cecile Le Deley, Kieran McHugh, Alicia Probst, Nathalie Rocourt, Rick R. van Rijn, Keith Wheatley, Veronique Minard-Colin, Julia C. Chisholm

Summary: The VIT-0910 trial aimed to evaluate the efficacy and safety of vincristine-irinotecan with and without temozolomide in relapsed or refractory rhabdomyosarcoma. The study found that the addition of temozolomide improved chemotherapy efficacy for patients with relapsed RMS, with manageable increase in toxicity. VIT is considered the new standard treatment in these patients in the European paediatric Soft Tissue Sarcoma Group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours

Reda Stankunaite, Sally L. George, Lewis Gallagher, Sabri Jamal, Ridwan Shaikh, Lina Yuan, Debbie Hughes, Paula Z. Proszek, Paul Carter, Grzegorz Pietka, Timon Heide, Chela James, Haider Tari, Claire Lynn, Neha Jain, Laura Rey Portela, Tony Rogers, Sucheta J. Vaidya, Julia C. Chisholm, Fernando Carceller, Elwira Szychot, Henry Mandeville, Paola Angelini, Angela B. Jesudason, Michael Jackson, Lynley Marshall, Susanne A. Gatz, John Anderson, Andrea Sottoriva, Louis Chesler, Michael Hubank

Summary: This study developed a clinically relevant NGS capture panel and workflow for detecting low frequency genetic variants in cell-free DNA from children with solid tumors. The method showed high sensitivity, specificity, repeatability, and reproducibility. The potential for clinical application was demonstrated in childhood cancer patients, with a close correlation between cfDNA events and treatment response observed.

EUROPEAN JOURNAL OF CANCER (2022)

Letter Oncology

VIT-0910: Need for Cautious Optimism? Reply

Anne-Sophie Defachelles, Emilie Bogart, Michela Casanova, Johannes H. M. Merks, Gianni Bisogno, Giuseppina Calareso, Soledad Gallego Melcon, Susanne Andrea Gatz, Marie-Cecile Le Deley, Kieran McHugh, Alicia Probst, Nathalie Rocourt, Rick R. van Rijn, Veronique Minard-Colin, Julia C. Chisholm

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas

Christopher I. Milton, Joanna Selfe, Ewa Aladowicz, Stella Y. K. Man, Carolina Bernauer, Edoardo Missiaglia, Zoe S. Walters, Susanne A. Gatz, Anna Kelsey, Melanie Generali, Gary Box, Melanie Valenti, Alexis de Haven-Brandon, David Galiwango, Angela Hayes, Matthew Clarke, Elisa Izquierdo, David Gonzalez De Castro, Florence I. Raynaud, Vladimir Kirkin, Janet M. Shipley

Summary: High expression of FGFR2 and FGF7 in fusion-gene-positive rhabdomyosarcomas correlates with increased sensitivity of the cells and forms a novel autocrine loop mechanism. FGFR inhibitor NVP-BGJ398 reduces cell viability and shows synergistic effects with SN38.

MOLECULAR ONCOLOGY (2022)

Article Oncology

Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study

Olivia Ruhen, Nathalie S. M. Lak, Janine Stutterheim, Sara G. Danielli, Mathieu Chicard, Yasmine Iddir, Alexandra Saint-Charles, Virginia Di Paolo, Lucia Tombolan, Susanne A. Gatz, Ewa Aladowicz, Paula Proszek, Sabri Jamal, Reda Stankunaite, Deborah Hughes, Paul Carter, Elisa Izquierdo, Ajla Wasti, Julia C. Chisholm, Sally L. George, Erika Pace, Louis Chesler, Isabelle Aerts, Gaelle Pierron, Sakina Zaidi, Olivier Delattre, Didier Surdez, Anna Kelsey, Michael Hubank, Paolo Bonvini, Gianni Bisogno, Angela Di Giannatale, Gudrun Schleiermacher, Beat W. Sch Safer, Godelieve A. M. Tytgat, Janet Shipley

Summary: This study aimed to explore the feasibility of using ctDNA in plasma as a marker for determining disease burden and treatment response in rhabdomyosarcomas (RMS). The results showed the presence of ctDNA in both mouse models and patients, and it was correlated with tumor burden and treatment response. This suggests that ctDNA has the potential to serve as a minimally invasive biomarker. Further evaluation through pre-clinical assessment using mouse models and prospective clinical trials in patients is warranted to validate these findings.

JCO PRECISION ONCOLOGY (2022)

No Data Available